Anaptysbio (ANAB) Profit After Tax (QoQ) (2016 - 2026)

Anaptysbio (ANAB) Profit After Tax (QoQ) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Anaptysbio 1.54 Bn 1.26 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -206.84%
Dec 31, 2025 228.29%
Sep 30, 2025 139.12%
Jun 30, 2025 2.14%
Mar 31, 2025 -81.20%
Dec 31, 2024 31.23%
Sep 30, 2024 32.11%
Jun 30, 2024 -6.20%
Mar 31, 2024 -4.09%
Dec 31, 2023 -13.14%
Sep 30, 2023 6.37%
Jun 30, 2023 9.96%
Mar 31, 2023 -112.48%
Dec 31, 2022 41.57%
Sep 30, 2022 -9.50%
Jun 30, 2022 10.21%
Mar 31, 2022 -10.01%
Dec 31, 2021 -392.62%
Sep 30, 2021 -1,459.44%
Jun 30, 2021 97.64%